Compound Profiles
CJC-1295 with DAC
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..
Teriparatide
PTH(1-34) | Bone-Building Anabolic Peptide
Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity.
Combined Organ Load
Frequently Asked Questions
Can I take CJC-1295 with DAC with Teriparatide?
Yes, CJC-1295 with DAC and Teriparatide can generally be taken together. CJC-1295 with DAC and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Is CJC-1295 with DAC and Teriparatide safe together?
Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.
What are the interactions between CJC-1295 with DAC and Teriparatide?
CJC-1295 with DAC and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time CJC-1295 with DAC and Teriparatide?
CJC-1295 with DAC has a half-life of 6-8 days and Teriparatide has a half-life of ~1 hour (subcutaneous); ~5 minutes (intravenous). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.